Dapagliflozin at Discharge on Hospital Heart Failure Readmission

Summary

This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D) after hospital admission for heart failure.

Timeline

Start

2020-07-29

Primary completion

2022-03-03

Completion

2022-03-03

Drugs

Indications